Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...

Symptom screening improved symptom scores among children with cancer compared with usual care, two randomized trials showed.

The new board member appointments include: A new independent director: George Llado, the former Senior Vice President and Chief Information Officer of Alexion Pharmaceuticals, Inc. George has more ...

The new board member appointments include: A new independent director: George Llado, the former Senior Vice President and Chief Information Officer of Alexion Pharmaceuticals, Inc. George has more ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, Novem ...

Mr. Tanguler brings over 25 years of senior leadership experience across notable organizations including Alnylam, Alexion ...

Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; ...

Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data esta ...

Merck and AstraZeneca's MEK inhibitor Koselugo (selumetinib) showed significant improvement in adult neurofibromatosis type 1 ...